Silver Book Fact

Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.

Harris, Steven T., Nelson Watts, Harry Genant, Clark McKeever, Thomas Hangartner, Michael Keller, Charles Chesnut III, Jacques Brown, Erik F. Eriksen, Mohammad Hoseyni, Douglas Axelrod, and Paul Miller. Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women with Postmenopausal Osteoporosis: a Randomized Controlled Trial. JAMA. 1999; 282(14): 1344-52. http://jama.ama-assn.org/cgi/content/abstract/282/14/1344

Reference

Title
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women with Postmenopausal Osteoporosis: a Randomized Controlled Trial
Publication
JAMA
Publication Date
1999
Authors
Harris, Steven T., Nelson Watts, Harry Genant, Clark McKeever, Thomas Hangartner, Michael Keller, Charles Chesnut III, Jacques Brown, Erik F. Eriksen, Mohammad Hoseyni, Douglas Axelrod, and Paul Miller
Volume & Issue
Volume 282, Issue 14
Pages
1344-52
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.  
  • A study that looked at a combination of calcium and Vitamin D found that hip fractures were reduced by around 43%.  
  • A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took…  
  • A meta-analysis of clinical trials found that calcium supplements reduced the risk of vertebral fractures by around 23%.